Summary
14.44 -1.00(-6.48%)06/28/2024
Verona Pharma Plc (VRNA)
Verona Pharma Plc (VRNA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -6.20 | -4.05 | 16.08 | -10.25 | -28.41 | -30.44 | 183.14 | 6.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 14.44 | |
| Open | 15.20 | |
| High | 15.33 | |
| Low | 14.14 | |
| Volume | 1,855,874 | |
| Change | -0.96 | |
| Change % | -6.20 | |
| Avg Volume (20 Days) | 2,021,655 | |
| Volume/Avg Volume (20 Days) Ratio | 0.92 | |
| 52 Week Range | 11.40 - 23.07 | |
| Price vs 52 Week High | -37.41% | |
| Price vs 52 Week Low | 26.67% | |
| Range | -5.00 | |
| Gap Up/Down | -0.85 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,115 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 20.83 | |
| Book Value | 2.8170 | |
| Earnings Per Share | -1.0030 | |
| EPS Estimate Current Quarter | -0.3700 | |
| EPS Estimate Next Quarter | -0.4700 | |
| EPS Estimate Current Year | -1.0700 | |
| EPS Estimate Next Year | -1.6500 | |
| Diluted EPS (TTM) | -1.0030 | |
| Revenues | ||
| Profit Marging | -1.4283 | |
| Operating Marging (TTM) | -1.4109 | |
| Return on asset (TTM) | -0.1577 | |
| Return on equity (TTM) | -0.3123 | |
| Revenue TTM | 40,000,000 | |
| Revenue per share TTM | 0.6830 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.7054 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 2.3502 | |
| Shares | ||
| Shares Outstanding | 60,010,400 | |
| Shares Float | 42,580,959 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.02 | |
| Institutions (%) | 63.01 | |
06/30 09:00 EST - seekingalpha.com
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.
06/27 09:49 EST - benzinga.com
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
06/27 09:03 EST - reuters.com
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
06/26 17:13 EST - reuters.com
US FDA approves Verona Pharma's therapy for 'smoker's lungs'
The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
US FDA approves Verona Pharma's therapy for 'smoker's lungs'
The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
06/26 16:57 EST - globenewswire.com
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.
05/09 12:31 EST - seekingalpha.com
Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Tom Shrader - BTIG Ram Selvaraju - H.C. Wainwright Operator Hello, and welcome to Verona Pharma's First Quarter 2024 Financial Results and Operating Highlights Conference Call.
Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Tom Shrader - BTIG Ram Selvaraju - H.C. Wainwright Operator Hello, and welcome to Verona Pharma's First Quarter 2024 Financial Results and Operating Highlights Conference Call.
05/09 07:15 EST - globenewswire.com
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.
05/09 07:00 EST - globenewswire.com
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities
05/02 02:00 EST - globenewswire.com
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces eight posters, including two mini oral symposia, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the American Thoracic Society International Conference (“ATS”) 2024.
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces eight posters, including two mini oral symposia, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the American Thoracic Society International Conference (“ATS”) 2024.
04/25 02:00 EST - globenewswire.com
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
03/04 02:00 EST - globenewswire.com
Andrew Fisher Joins Verona Pharma as General Counsel
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr.
Andrew Fisher Joins Verona Pharma as General Counsel
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr.
03/01 08:45 EST - fool.com
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.
02/29 02:00 EST - globenewswire.com
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m. EST / 2:00 p.m.
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m. EST / 2:00 p.m.
02/15 02:00 EST - globenewswire.com
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
02/01 02:00 EST - globenewswire.com
Michael Austwick Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.
Michael Austwick Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.
01/03 02:00 EST - globenewswire.com
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
01/02 02:00 EST - globenewswire.com
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
Strengthens financial flexibility to support the Company's continued growth Strengthens financial flexibility to support the Company's continued growth
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
Strengthens financial flexibility to support the Company's continued growth Strengthens financial flexibility to support the Company's continued growth
12/30 06:50 EST - fool.com
3 Stocks That Could Be Monster Winners in 2024
CRISPR Therapeutics' innovative gene-editing therapy could be a game changer. Madrigal Pharmaceuticals hopes to soon win U.S. approval for a potential blockbuster NASH drug.
3 Stocks That Could Be Monster Winners in 2024
CRISPR Therapeutics' innovative gene-editing therapy could be a game changer. Madrigal Pharmaceuticals hopes to soon win U.S. approval for a potential blockbuster NASH drug.
12/22 11:17 EST - zacks.com
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
11/23 11:16 EST - zacks.com
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
The consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
The consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.